Clinical Trial
PNOC005: A phase 1 study of modified measles virus for the treatment of children and young adults with recurrent medulloblastoma or recurrent atypical teratoid rhabdoid tumors (ATRT)
PNOC005 Study Publication
PNOC005 is now closed, and clinical trial results are now available as published in the Clinical Cancer Research in July 2025.
viewable here:
For children with recurrent medulloblastoma or ATRT, outcomes remains very poor. Preclinical studies have shown that treatment with modified, attenuated measles virus (MV-NIS) leads to prolonged survival in models of recurrent medulloblastoma and ATRT. Safety studies have proven that MV-NIS has an excellent safety profile and ongoing adult studies are currently testing MV NIS in adult glioblastoma, ovarian cancer, and multiple myeloma.
PRIMARY OBJECTIVES
Strata A & B: To determine the safety and recommended phase 2 dose of modified measles virus if administered into the tumor bed of patients with locally recurrent medulloblastoma or ATRT or into the subarachnoid space of patients with disseminated medulloblastoma or ATRT.
Stratum C: To determine the safety of two administrations of modified measles virus if administered into the subarachnoid space of patients with disseminated recurrent medulloblastoma.
Funding is provided by No More Kids with Cancer and Solving Kids’ Cancer.
PNOC005 Study Publication
PNOC005 is now closed, and clinical trial results are now available as published in the Clinical Cancer Research in July 2025.
viewable here:
For children with recurrent medulloblastoma or ATRT, outcomes remains very poor. Preclinical studies have shown that treatment with modified, attenuated measles virus (MV-NIS) leads to prolonged survival in models of recurrent medulloblastoma and ATRT. Safety studies have proven that MV-NIS has an excellent safety profile and ongoing adult studies are currently testing MV NIS in adult glioblastoma, ovarian cancer, and multiple myeloma.
PRIMARY OBJECTIVES
Strata A & B: To determine the safety and recommended phase 2 dose of modified measles virus if administered into the tumor bed of patients with locally recurrent medulloblastoma or ATRT or into the subarachnoid space of patients with disseminated medulloblastoma or ATRT.
Stratum C: To determine the safety of two administrations of modified measles virus if administered into the subarachnoid space of patients with disseminated recurrent medulloblastoma.
Funding is provided by No More Kids with Cancer and Solving Kids’ Cancer.
Sites Offering This Trial
- CHICAGO, IL Ann & Robert H. Lurie Children’s Hospital of Chicago
- LOS ANGELES, CA Children’s Hospital Los Angeles
- COLUMBUS, OH Nationwide Children’s Hospital
- ST. LOUIS, MO St. Louis Children’s Hospital
- SEATTLE, WA Seattle Children’s Hospital
- PHILADELPHIA, PA The Children’s Hospital of Philadelphia
- San Francisco, CA UCSF Benioff Children’s Hospitals
- GAINESVILLE, FL University of Florida Shands Children’s Hospital
- SALT LAKE CITY, UT University of Utah
How to Enroll
If you believe your child or patient is eligible for this trial, contact the closest participating site or email us for more information.